{
    "nctId": "NCT01261832",
    "officialTitle": "Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent",
    "inclusionCriteria": "Acute Myocardial Infarction Undergoing Primary percutaneous coronary intervention.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "1. The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Cilostazol\n2. Uncontrolled hypertension\n3. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.\n4. Baseline hemogram with Hb\\<10g/dL or PLT count\\<100,000/\u03bcL\n5. Patients already taking warfarin, cilostazol or any other type of anti-platelet agents except aspirin and clopidogrel\n6. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.\n7. Pregnancy"
}